Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BDTX 
Black Diamond Therapeutics Inc (BDTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: BDTX (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9
1 Year Target Price $9
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 95.63% | Avg. Invested days 42 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 153.26M USD | Price to earnings Ratio 7.27 | 1Y Target Price 9 |
Price to earnings Ratio 7.27 | 1Y Target Price 9 | ||
Volume (30-day avg) 4 | Beta 3.34 | 52 Weeks Range 1.20 - 4.94 | Updated Date 12/4/2025 |
52 Weeks Range 1.20 - 4.94 | Updated Date 12/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.37 |
Earnings Date
Report Date 2025-11-06 | When - | Estimate -0.235 | Actual -0.15 |
Profitability
Profit Margin 30.71% | Operating Margin (TTM) 21.15% |
Management Effectiveness
Return on Assets (TTM) 6.26% | Return on Equity (TTM) 19.23% |
Valuation
Trailing PE 7.27 | Forward PE 8.33 | Enterprise Value 80730449 | Price to Sales(TTM) 2.19 |
Enterprise Value 80730449 | Price to Sales(TTM) 2.19 | ||
Enterprise Value to Revenue 1.15 | Enterprise Value to EBITDA 6.62 | Shares Outstanding 56974913 | Shares Floating 39325794 |
Shares Outstanding 56974913 | Shares Floating 39325794 | ||
Percent Insiders 0.65 | Percent Institutions 79.44 |
Upturn AI SWOT
Black Diamond Therapeutics Inc
Company Overview
History and Background
Black Diamond Therapeutics, Inc. is a precision oncology medicine company that was founded in 2014. It focuses on developing MasterKey therapies that selectively target cancer-causing mutations. The company went public in January 2020.
Core Business Areas
- Oncology Drug Development: Focuses on discovering and developing small molecule, tumor-agnostic therapies that target allosteric mutations in oncogenes.
Leadership and Structure
David M. Epstein is the President and Chief Executive Officer. The company has a board of directors and a management team focused on research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- BDTX-1134: BDTX-1134 is an orally available, brain-penetrant MasterKey inhibitor of EGFR, a receptor tyrosine kinase, targeting a range of EGFR allosteric and classical activating mutations in patients with non-small cell lung cancer (NSCLC). The competitors include Tagrisso (AZN), but it targets EGFR mutations differently.
- BDTX-4933: BDTX-4933 is a selective inhibitor of the oncogenic kinases NRAS and BRAF. It is in preclinical development to treat tumors driven by NRAS and BRAF. Competitors are BRAFTOVI (Array BioPharma, now Pfizer) and MEKTOVI (Array BioPharma, now Pfizer).
Market Dynamics
Industry Overview
The oncology drug market is a large and competitive market with increasing demand for targeted therapies and precision medicine approaches.
Positioning
Black Diamond Therapeutics focuses on a niche within the oncology market: allosteric mutations. This offers a potential advantage over traditional kinase inhibitors.
Total Addressable Market (TAM)
The total addressable market is in the billions, encompassing a significant number of cancer patients with specific oncogenic mutations. Black Diamond aims to capture a portion of this by addressing unmet needs.
Upturn SWOT Analysis
Strengths
- Novel approach targeting allosteric mutations
- Proprietary drug discovery platform (MAP platform)
- Experienced leadership team
- Potential for tumor-agnostic therapies
Weaknesses
- Clinical stage risks associated with drug development
- High cash burn rate
- Reliance on success of pipeline programs
- Small market capitalization
Opportunities
- Expanding pipeline to target additional oncogenes
- Partnerships with larger pharmaceutical companies
- Potential for breakthrough therapy designation
- Expanding indications for existing pipeline assets
Threats
- Competition from existing therapies
- Regulatory hurdles and delays
- Failure to demonstrate clinical efficacy
- Patent challenges
Competitors and Market Share
Key Competitors
- AZN
- PFE
- MRTX
Competitive Landscape
BDTX competes with larger, established pharmaceutical companies. Its advantage lies in its novel approach, but it faces challenges in terms of resources and market access.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by advancement of pipeline programs and successful financing rounds.
Future Projections: Future growth is dependent on clinical trial success, regulatory approvals, and commercialization of products. Analyst estimates vary based on pipeline progress.
Recent Initiatives: Recent initiatives include advancing BDTX-1134 into clinical trials and expanding the pipeline with new programs.
Summary
Black Diamond Therapeutics is a clinical-stage oncology company with a novel approach to treating cancer. It focuses on allosteric mutations, potentially creating more effective targeted therapies. However, as a small cap biotech company, it has inherent risks, including clinical trial failures, high cash burn and the need to raise more money to fund it's programs. The company will need to successfully navigate these challenges to achieve long-term success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data may be outdated. Market share data is an estimate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Black Diamond Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2020-01-30 | CEO, President & Chairman Dr. Mark A. Velleca M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 24 | |
Full time employees 24 | |||
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.